Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Colleen Kelly, Morgan Paul, Wendy London, Rahela Aziz-Bose, Puja Umaretiya, Erica Esrick, Victoria Coleman-Cowger, Gary Schiller, Mehrdad Abedi, Joseph Antin, Mary Horowitz, Neena Kapoor, Edmund Waller, Sonali Chaudhury, Mary Eapen, Mark Walters, David Williams, Kira Bona

Blood (2025) 146 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2025-6224

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie, Gabriel Mannis, Justin Watts, Farhad Ravandi, Gary Schiller, Brian Ball, Hongtao Liu, Jessica Altman, Eunice Wang, J. Jean Cui, Jihao Zhou, Zachary Zimmerman, Stephen Strickland

Blood (2025) 146 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2025-1655

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

Guillermo Garcia-Manero, Yazan Madanat, Mikkael Sekeres, Hetty Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary Schiller, Frank Hsu, Toufigh Gordi, Lisa Rojkjaer, Lewis R Silverman

Blood (2025) 146 (Supplement 1): 489.

https://doi.org/10.1182/blood-2025-489

Published: 2025

Journal Articles

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Blood (2025) 146 (Supplement 1): 768.

https://doi.org/10.1182/blood-2025-768

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Brian Garrison, Rochelle Emery, Kanya Rajangam, Gary Schiller, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2025-1044

Published: 2025

Journal Articles

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Deepa Jeyakumar, An To, Piyanuch Kongtim, Kiran Naqvi, Pamela Becker, Brian Jonas, Caspian Oliai, Gary Schiller, Matthew Wieduwilt, Lloyd Damon

Blood (2025) 146 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2025-5241

Published: 2025

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Blood (2025) 146 (Supplement 1): 6094.

https://doi.org/10.1182/blood-2025-6094

Published: 2025

Journal Articles

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Chadi Nabhan, Jeremy Abramson, Tyler Fraum, Ajay Nooka, Gary Schiller, David Schuster, Michael Thirman, Kayla Haines, Erin Shonkwiler, Mohammad Jahanzeb

Blood (2025) 146 (Supplement 1): 4359.

https://doi.org/10.1182/blood-2025-4359

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Associations between chronic kidney disease, proteinuria, and thrombotic risk in SCD

Mary Sehl, Qin SUN, Nicole Herrera, Sam Walters, Amie Patel, Samuel Wilson, Gary Schiller, John Strouse

Blood (2025) 146 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2025-1184

Published: 2025

Journal Articles

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.

Jacqueline Hsieh-Wong, Naseem Esteghamat, Rasmus Hoeg, Mehrdad Abedi, Sheila Firoozan, Aaron Rosenberg, Ashley Trane, Aneeqa Zafar, Shuai Chen, Siyao Li, Matthew Wieduwilt, Lloyd Damon, Benjamin Heyman, Haifaa Abdulhaq, Elizabeth Brem, Deepa Jeyakumar, Gary Schiller, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2025-1966

Published: 2025

Journal Articles

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5921.

https://doi.org/10.1182/blood-2025-5921

Published: 2025

Journal Articles

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Zachariah DeFilipp, Hannah Choe, Yvonne A. Efebera, Ayman Saad, Shatha Farhan, Lazaros Lekakis, Jean A. Yared, Gary Schiller, Markus Y. Mapara, Amer Assal, Ted Gooley, Jack D. Bui, Dana Lee, Hayley Lane, Yi-Bin Chen

Blood (2025) 146 (17): 2037–2046.

https://doi.org/10.1182/blood.2025029584

Published: 2025

Includes: Supplemental data

Journal Articles

Access to AlloTx for AML: the value of the social phenotype

Gary Schiller

Blood (2025) 145 (25): 2941–2942.

https://doi.org/10.1182/blood.2025028826

Published: 2025

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Associations between chronic kidney disease, proteinuria, and thrombotic risk in SCD

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Access to AlloTx for AML: the value of the social phenotype

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only